Form 4 for WHWK Whitehawk Therapeutics, Inc.
Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-04 · accession 0001415889-25-007096 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-03-05 | 2025-03-04 | WHWK | Dalal Anupam | Dir | A - Grant | $2.40 | +1.56M | 3.41M | +84% | +$3.75M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | A | A | 1,561,000 | $2.40 | 3,410,402 | I See footnote | — | — | (F1) Consists of (i) 2,535,488 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 874,914 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein. |